8/14/2020 8:09:37 AM
Celsion Q2 Loss/Shr $0.18 Vs Loss $0.29 Last Year
7/13/2020 8:41:03 AM
Celsion Receives Recommendation From Independent DMC To Consider Stopping Phase III OPTIMA Study
3/23/2020 8:15:48 AM
Celsion: GEN-1 Immunotherapy Receives Orphan Drug Designation From EMA
2/28/2020 8:50:23 AM
Celsion Prices $4.8 Mln Direct Offering
6/20/2019 8:38:10 AM
Celsion Announces IRB Approval To Begin Clinical Study Of ThermoDox Plus HIFU
12/18/2018 8:22:54 AM
DMC Completes Planned Safety And Data Review Of Celsion’s Phase III OPTIMA Study Of ThermoDox
12/3/2018 9:22:39 AM
Celsion Receives $11.1 Mln Allocation Through New Jersey Technology Business Tax Certificate Transfer Program
10/24/2018 9:27:09 AM
Celsion Announces PFS Data From GEN-1 Phase I Immuno-Oncology Study Of Patients With Stage III/IV Ovarian Cancer
10/22/2018 9:23:17 AM
Celsion Announces Publication Highlighting Potential Of Celsion's Gene-Mediated Immunotherapy
9/5/2018 8:12:37 AM
Celsion Announces Enrollment Completion For Pivotal Phase III OPTIMA Study Of ThermoDox In Primary Liver Cancer
7/10/2018 8:09:35 AM
Celsion Announces Publication Of Thermodox Phase I Study Results In The Lancet Oncology